DENVER, CO and CHICAGO, IL--(Marketwire - January 15, 2009) - GeneThera, Inc. (PINKSHEETS: GTHR) announced today it has secured the services of crowdSPRING, based in Chicago, to develop the company’s new logo and company branding symbols.
GeneThera chose the theme “New Beginning” due to the new beginnings within biotechnology and the company itself. Recently, GeneThera stated it was moving from being focused on R&D to focusing on revenue generating. As part of this transformation, the company is currently re-designing its corporate branding and image, which will be incorporated in its new website. The new GeneThera.net site should be finished by the end of January.
“We want a young, vibrant, and forward-looking feel with our logo and branding,” noted Tony Milici. “One of the interesting approaches crowdSPRING uses is by letting all interested graphic designers submit their entry for a logo they feel suits our needs. The public will be able to view all entries and vote for their favorite. This new logo will be incorporated into our website, brochures, PowerPoint presentations, press kits, upcoming YouTube videos, and more. This is truly a collaborative process.”
All interested graphics designers need to go to the following webpage in order to submit their entry:
Once there, simply click on the “Participate Now” link on the right.
For the public to vote on their favorite logo, please go to the same webpage:
Simply view the entries as they are received, click on them for more details and click on the “People love it” link below the image to cast your vote.
Please feel free to vote on as many as you like, as often as you like. The winning entry will be announced Tuesday, January 20th.
ABOUT GENETHERA, INC.
GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colorado. The Company’s proprietary diagnostic solution is based on a genetic expression assay, GES™, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, E. coli 0157:H7 and Johne’s disease. For more information, contact Al Goldsmith of The Goldsmith Group LLC at 303-463-6371 Ext. 206.
This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “intends,” “believes,” and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company’s filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
Dr. Tony Milici
303-463-6371
Goldsmith Group
303-838-4370
JR Dopkin & Associates
516-884-3200
